Former Director General of the Italian Medicines Agency (AIFA), Dr Luca Pani joins Nurosene as Chief Medical Advisor
Strengthening Nurosene’s understanding of the brain and mental health, Dr. Luca Pani joins a global council of thought leaders
TORONTO, June 28, 2021 / CNW / – Nurosene Health Inc. (“Nurosene” or the “Company”) (CSE: MEND), a health technology company focused on mental wellness, today announced that Dr. Luca Pani, MD has been appointed Chief Medical Advisor and will be part of its Mental Health Advisory Board. Dr Pani Joins a Global Council of Thought-Leaders with Unique and Diverse Expertise in Medicine, Athletics and Technology, including the NFL Superstar Richard sherman and decorated Olympian Michael Phelps.
Dr Pani was Director General of the Italian Medicines Agency (AIFA) for five years and currently sits on several boards, including the Committee for Medicinal Products for Human Use (CHMP) and the Working Group on Scientific Advice (SAWP) for the European Medicines Agency. He was also elected chairman of the EU telematics committee responsible for the European Medicines Agency (EMA) database transition plan.
In his current role, Dr Pani is Professor of Pharmacology and Clinical Pharmacology at the University of Modena and Reggio Emilia in Italy and professor of clinical psychiatry at the Miami University, United States. He is also Vice President of Regulatory Strategy and Market Access Innovation at VeraSci in Durham, North Carolina and the chief advisor for Relmada’s drug development pipeline.
“I couldn’t be more excited to help fuel the growth of a company with a great vision and purpose. Mental health and wellness is something that affects us all universally. I couldn’t be more proud to be part of the Nurosene team, ”said Dr Pani.
Dr Pani is a recognized expert in basic and clinical pharmacology with a particular focus on health technology assessments and is the author of over 180 scientific publications. His in-depth expertise in large web-based clinical data sets will help guide Nurosene’s innovation efforts and lead the company’s mental health advisory board with respect to potential medical solutions in the market.
“We are delighted that Dr. Pani is guiding us through this journey. His in-depth knowledge and expertise in clinical psychiatry and pharmacology will strengthen our NURO app and be of great value to us as we build our NURO toolbox. Dr. Pani will guide our research initiatives at Nurosene and we are delighted to benefit from his extensive experience working with FDA protocols, ”said Ranj bath, CEO of Nurosene.
Nurosene provides individuals with tools and technologies that allow them to take control of their mental well-being. Its mission is to build the next generation of better, healthier brains by leveraging technological advances in AI and machine learning. With its team of experts and partners, Nurosene is positioned at the forefront of research and critical innovations, striving to disrupt traditional mental wellness treatments. The company is based in Toronto, Ontario.
For more information visit www.nurosene.com
This press release contains “forward-looking information” within the meaning of applicable Canadian securities laws, which is based on Nurosene’s current internal expectations, estimates, projections, assumptions and beliefs, as well as its opinions on future events. . Forward-looking information can be identified by the use of forward-looking terms such as “expect”, “likely”, “could”, “will”, “should”, “intend”, “anticipate”, “. proposed “,” estimate “and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions” could “,” would “or” will “occur, or by strategy discussions. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, indications or other statements that are not statements of fact. Specifically, this press release release contains forward-looking statements regarding, among other things, the activities of the Society’s Mental Health Advisory Board, the Society’s research activities and Dr. Pani’s contributions thereto.
Any forward-looking information is only valid as of the date it is made and, except as required by law, Nurosene assumes no obligation to update or revise any forward-looking information, whatsoever thereafter. new information, future events, or whatever. New factors appear from time to time, and it is not possible for Nurosene to predict all of these factors. When reviewing these forward-looking statements, readers should keep in mind the risk factors and other caveats in Nurosene’s final detailed prospectus dated May 20, 2021 and filed with the relevant Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors mentioned in Nurosene’s final long-form prospectus could cause actual events or results to differ materially from those described in any forward-looking information.
The CSE accepts no responsibility for the adequacy or accuracy of this release.
SOURCE Nurosene Health Inc.
For more information: KCSA Strategic Communications, Valter Pinto, Managing Director, [email protected], (212) 896-1254; Blake Sing, Chief Financial Officer, [email protected], (416) 859-8838